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A B S T R A C T
Objective: Neuroplasticity can be deﬁned as the ability of the brain to adapt to environmental impacts.
These adaptations include synapse formation and elimination, cortical reorganization, and neurogenesis.
In epilepsy these mechanisms may become detrimental and contribute to disease progression. It has
been proposed that Matrix Metalloproteinase 9 (MMP-9), a proteinase that cleaves extracellular matrix
molecules, may be critically involved in aberrant synaptic formation in hippocampi of patients with
Temporal Lobe Epilepsy (TLE). Here we present a case–control study designed to identify possible
variants of the MMP-9 gene associated with human TLE.
Material and methods: 218 Norwegian patients with TLE and 181 ethnically matched controls were
compared in our association analysis.We also studied associations within two subgroups of TLE –Mesial
Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS), and Temporal Lobe Epilepsy with
childhood Febrile Seizures (TLE-FS). Single nucleotide polymorphisms (SNPs) were selected from
HapMap and dbSNP databases for the MMP-9 gene on chromosome 20. We used standard haplotype
analysis and multivariate explorative analysis.
Results: There were no statistically signiﬁcant associations between the analyzed SNPs in the MMP-9
gene and TLE, nor were any signiﬁcant associations found with the two examined subgroups MTLE-HS
and TLE-FS, conﬁrmed by both analyses.
Conclusion: We could not identify any polymorphisms of the human MMP-9 gene that were associated
with TLE, MTLE-HS or TLE-FS, in the selected SNPs. However, factors that inﬂuence MMP-9 gene
expression, post-transcriptional modiﬁcations, or the balance between activation and inhibition of
MMP-9 may play a role in the pathogenesis of TLE and other epileptic syndromes.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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One fundamental characteristic of the human brain is its
astonishing capacity to undergo life long functional and morpho-
logical changes. These processes, also collectively referred to as
remodeling, include synapse formation and elimination, cortical
reorganization and neurogenesis. Remodeling occurs during brain
development and learning, but also serves as an adaptive
mechanism to compensate for lost function.1–3 Studies of theAbbreviations: ECS, extracellular space; ECM, extracellular matrix; FS, febrile
seizure; HS, hippocampal sclerosis; MMP, Matrix Metalloproteinase; MMP-9,
Matrix Metalloproteinase 9; MTLE, Mesial Temporal Lobe Epilepsy; MTLE-HS,
Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis; TLE, Temporal Lobe
Epilepsy; TLE-FS, Temporal Lobe Epilepsy with Febrile Seizures.
* Corresponding author. Tel.: +47 230 70472; fax: +47 230 70490.
E-mail address: kjell.heuser@oslo-universitetssykehus.no (K. Heuser).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.05.003hippocampus have disclosed a relation between synaptic remo-
deling and epilepsy.3–5 In Temporal Lobe Epilepsy (TLE), especially
in cases with hippocampal sclerosis, remodeling may lead to
defective synaptic rearrangement of neuronal circuits and thus
promote epileptogenesis and disease progression.6
TLE is a serious, chronic neurological condition characterized by
recurrent seizures that originate in the temporal lobe. TLE is
common as it probably accounts for about one-third of all patients
with epilepsy.7 A major burden for patients with this condition is
the frequent resistance to pharmacotherapy, and temporal
lobectomy may be required to achieve seizure control.8 There is
thus an urgent need to develop new treatment strategies for this
disease.
TLE is often associated with hippocampal alterations which are
known to play a critical role in epileptogenesis. These alterations
include sprouting of mossy ﬁbres and aberrant formation of
excitatory synapses in speciﬁc regions of the hippocampus. Thevier Ltd. All rights reserved.
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of hippocampal epileptogenesis are unknown.
A recent discovery is the identiﬁcation of Matrix Metallopro-
teinase 9 (MMP-9) as a possible key factor in the development of
aberrant synaptic plasticity and dendritic pruning in TLE hippo-
campi.9 MMP-9 is a proteinase that cleaves extracellular matrix
molecules in and around the synaptic cleft and MMP-9 activation
may be an essential step in the cascade of events leading to new
synapse formation. Speciﬁcally, the synaptic pool of MMP-9 could
be critical for the sequence of events that underlie the develop-
ment of seizures in TLE.
As transgenic rats overexpressing MMP-9 develop increased
susceptibility to seizures, and deletion of the MMP-9 gene in mice
leads to less severe seizures,9 we hypothesized that particular
polymorphisms of the MMP-9 gene could contribute to the
development of Temporal Lobe Epilepsy, or subgroups of this
condition, notably Mesial Temporal Lobe Epilepsy with Hippo-
campal Sclerosis (MTLE-HS), and Temporal Lobe Epilepsy with
childhood Febrile Seizures (TLE-FS).
In the current paper we highlight an attractive mechanistic
hypothesis of the relation between TLE and MMP-9 and present an
association study designed to identify possible variants of the
MMP-9 gene associated with TLE or its subgroups MTLE-HS and
TLE-FS.
2. Material and methods
2.1. Selection of subjects
In total, 399 individuals were included in the study – 218
patientswith TLE (according to the ILAE criteria, seewww.ilae.org),
and 181 healthy controls (without history of epilepsy or febrile
seizures). Blood samples were collected between 2000 and 2004 in
a cooperative project, involving seven tertiary Norwegian centers
with high competence in the ﬁeld of epileptology. Inclusion criteria
for all individuals were: age > 18 years; Caucasian race, with at
least 3 of 4 grandparents of Scandinavian origin. The controls had
no known familial relation to the TLE patients (typically spouse or
partner). Standardized evaluation forms were used for all TLE
patients and controls in addition to an overhaul of the patient
records. MRI (typically 1 or 1.5 T, with sagittal and axial T1, axial
and coronal T2 and FLAIR) was performed in all 218 patients in
order to differentiate cases with hippocampal sclerosis (MTLE-HS).
We detected 56 patients with MTLE-HS and 162 cases with other
TLE. 102 TLE patients were found to have had childhood febrile
seizures versus 105 without. 11 patients were excluded because ofTable 1
Polymorphic MMP-9 SNPs, ordered by region on chromosome 20.
Rs number Region Source Alleles
rs3918279 44069902 dbSNP CC/CT
rs1805088 44071031 HapMap CC/CT
rs41427445 44071085 dbSNP AA/AG
rs6017724 44070187 dbSNP AG/GG
rs3918253 44072918 HapMap CC/CT/TT
rs55789927 44073006 dbSNP CC/CT
rs2274755 44073099 HapMap GG/GT
rs17576 44073632 HapMap AA/AG/GG
rs2236416 44073982 dbSNP AA/AG/GG
rs6104427 44076255 HapMap AA/GG
rs2274756 44076518 HapMap AA/AG/GG
rs3918261 44076999 HapMap AA/AG/GG
rs3918262 44077177 dbSNP AA/AG/GG
rs3918282 44078116 dbSNP AG/GG
rs13925 4407837 dbSNP AA/AG/GG
rs20544 4407841 dbSNP CC/CT/TT
rs9509 4407856 dbSNP CT/TTunclear febrile seizure status. Written informed consent was
obtained from all participating individuals and the study was
approved by the regional ethical committee. The patient popula-
tion is previously characterized in detail.10
2.2. Validation and characterization of SNPs
SNP genotyping in all 218 cases and 181 controls was done
using the MassARRAY system from Sequenom, www.sequenom.-
com (San Diego, CA, USA). A total of 40 SNPs from the MMP-9 gene
on chromosome 20 were used in the assay design. The SNPs were
chosen from HapMap (www.hapmap.org) and from dbSNP
(www.ncbi.nlm.nih.gov/SNP). All SNPs that had a known allele
frequency, in Caucasian populations, in either of these databases
were included in the initial primer design. Genotype calls were
assigned in real time11 based on the mass peaks present, by using
the MassARRAY SpectroTYPER RT v3.4 software from Sequenom.
All the results were manually inspected, using the MassARRAY
TyperAnalyzer v4.0 software (Sequenom).
2.3. Analysis 1: Haploview analysis of single SNPs and haplotypes in
cases versus control groups
The HaploView 4.0 software package12 was used for deﬁning
haplotype blocks and to investigate possible associations between
single SNPs and haplotypes within blocks. Criterion for block
deﬁnition was as suggested by Gabriel et al.13 Both nominal p-
values and p-values corrected for multiple testing have been
considered. The boundary used for indicating signiﬁcance was set
to 5% for the single SNPs and haplotypes. Multiple corrections of
the p-values were determined by repeating 10,000 random
permutations of the case/control status.
2.4. Analysis 2: explorative data analysis
Coding of data, multivariate data analysis for SNP selection and
predictive modelling was used as in Heuser et al.14
3. Results
There were no associations between the analyzed SNPs in the
MMP-9 gene and TLE, nor were any associations found with the
two examined subgroups MTLE-HS and TLE-FS. Of the 40 tested
SNPs, 23 were monomorphic in this material and are therefore not
included in the analysis. Polymorphic SNPs included in this study
are listed in Table 1, ordered by their region on chromosome 20.Allele frequence Chi-square p-Value
[205,7;170,4] 0.347 0.556
[195,2;165,1] 0.187 0.665
[199,2;163,0] 1.631 0.202
[7,212;2,177] 1.926 0.165
[36,96,83;22,86,63] 1.675 0.433
[211,1;174,0] 0.823 0.364
[172,36;129,38] 1.735 0.188
[102,88,25;75,79,17] 1.127 0.569
[171,31,3;128,31,2] 1.110 0.574
[0,217;1,177] 1.222 0.269
[3,35,172;2,36,131] 1.342 0.511
[171,31,3;129,31,2] 1.056 0.590
[131,72,12;112,53,8] 0.635 0.728
[4,207;5,167] 0.422 0.516
[3,37,173;2,40,128] 2.245 0.325
[36,93,83;23,87,61] 2.060 0.357
[10,206;7,166] 0.078 0.780
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equilibrium.
4. Discussion
4.1. Temporal Lobe Epilepsy and epileptogenesis
TLE is of major clinical interest due to frequent resistance to
pharmacotherapy and its association with hippocampal sclerosis
(HS) and febrile seizures (FS). Animal models of TLE based on
chemically or electrically induced seizures have disclosed major
reorganization of hippocampal circuitries.15–18 This reorganiza-
tion includes neuronal loss, astrocyte proliferation, sprouting of
mossy ﬁbers, and aberrant formation of excitatory synapses in
speciﬁc regions of the hippocampus: dentate gyrus and Ammon’s
horn subﬁeld 3 (CA3). Notable changes are also found at the
molecular level, including the activation of second messenger
systems, immediate early genes, transcription factors, neuro-
trophic factors, and axon guidancemolecules.19 These changes are
associated with epilepsy development and progression, also
known as epileptogenesis.
More speciﬁcally, the term epileptogenesis refers to the
processes by which the non-epileptic brain is transformed into
one that generates spontaneous seizures, and it is also used as a
description of the further progression of brain tissue already
capable of generating chronic, recurrent, spontaneous symptom-
atic- or non-symptomatic seizures.20
From a clinical point of view, TLE patients, especially those with
HS, typically present with an initial precipitating incident (febrile
convulsion, trauma, hypoxia, intracranial infection, etc.) in early
childhood, followed by a seizure-free interval (latent or silent
period). Once habitual seizures begin, they are often initially
responsive to antiepileptic medication, before turning refractory.
This typical disease development is likely to correlate with the
biological processes that underlie epileptogenesis.21 Despite
growing knowledge about the quality and quantity of hippocampal
changes in TLE, the factors that precipitate such changes are still
unknown.
4.2. Temporal Lobe Epilepsy and Matrix Metalloproteinase 9
A novel approach to explaining epileptogenesis in TLE focuses
on the mechanisms of plasticity and synapse formation. Speciﬁ-
cally, this hypothesis provides a possible explanation of how
recurrent and inappropriate excitatory pathways are formed in the
hippocampi of TLE patients. The enzymeMatrix Metalloproteinase
9 (MMP-9) has been shown to directly affect the processes that
lead to such inappropriate excitatory loops9 that in turn are
thought to underlie epileptic activity. Matrix Metalloproteinases
(MMPs) constitute a family of zinc dependent extracellular or
membrane bound endopeptidases, subdivided according to their
substrate afﬁnities for different components of extracellular
matrix. Their primary function is the cleavage of extracellular
matrix (ECM) proteins and they are thus involved in processes of
physiological tissue remodeling.22
MMP-9 has been implicated in various CNS pathologies
including stroke,23 traumatic brain injury,24 cerebral arteriovenous
malformations,25 inﬂuenza associated encephalopathy,26 systemic
lupus erythematosus with CNS affection,27 and in meningitis,
where it has been identiﬁed as a risk factor for developing
neurological sequelae.28 In addition, recent studies have indicated
a physiological role of MMP-9 in neuronal plasticity, including
learning and memory as well as long-term-potentiation.29,30
Hence, it has been suggested that MMP-9 may have an initial
detrimental effect leading to neuronal cell loss but also a
subsequent beneﬁcial (restorative or neuroprotective) effect.31,32In relation to epilepsy, MMP-9 cleaves extracellular matrix
molecules in and around the synaptic cleft, where this is thought to
be a necessary step in the cascade of events leading to new synapse
formation. Wilczynski et al. have examined the role of MMP-9 in
TLE.9 Theyused twoanimalmodels of TLE in their study: exposure to
the neurotoxin kainate, and to chemical kindling using pentylene-
tetrazole (PTZ). In studying the effect of PTZ kindling on transgenic
mice with a deletion of the MMP-9 gene (MMP-9 /) they found
that the kindled MMP-9 / animals developed epilepsy at a later
stage and presented with less severe seizures than did the control,
WT animals. Having identiﬁed this protective effect of MMP-9 gene
deletion, the authors proceeded to investigate whether abundant
MMP-9 would enhance epileptogenesis. They generated a trans-
genic (TG) rat that overexpressed neuronal MMP-9. The kindling
experiment did indeed demonstrate an increased susceptibility to
epileptogenesis andmore severe seizures. This effect did not appear
until after the ﬁrst few injections, where the authors propose this is
evidence to suggest the involvement of a plastic process. These
results were underscored by a histological analysis showing that
aberrant synaptogenesis and mossy ﬁber sprouting were signiﬁ-
cantly reduced in thehippocampiofMMP-9/ animals exposed to
kainate. Overall, this experimental evidence emphasizes the role of
MMP-9 as an enzyme that directly affects remodeling of synaptic
linkage and that could represent a pharmacological target in
epilepsy treatment.
4.3. Association study of the MMP-9 gene in a Norwegian TLE cohort
Several lines of evidence are pointing towards an important role
of genetics in TLE, such as observations of familial monogenic
forms,8,33,34 the frequent presence of positive familial antecedents
for epileptic events,35 and high association with febrile seizures.36
In the past decade, genetic association studies in epilepsy
mainly focused on polymorphisms in synaptic ion channel genes,
with rather unsuccessful results.37 At the same time molecular
biological research provided novel candidate genes, based on
recent knowledge about other possible contributors to the
mechanisms of epileptogenesis, such as MMP-9. An important
question is whether genetic variants of the MMP-9 gene would
contribute to aberrant synaptic plasticity and formation of
epileptic foci. Based on the accumulating data that indicate a role
for MMP-9 in neuroplasticity and epileptogenesis, we hypothe-
sized that particular polymorphisms of the MMP-9 gene could
contribute to the development of TLE.
The validity of genetic association studies depends upon a
number of factors, which have been timely reviewed in relation to
research within the ﬁeld of epilepsy.37 Recent guidelines for
appraising genetic association studies in epilepsy might have
reduced methodological failures and the amount of published
association studies, but have not contributed to the disclosure of
single gene associations to the common epilepsies. These guide-
lines were stringently adhered to in establishing the protocol for
our study, reﬂected by the following: we used a clearly deﬁned
phenotype; we had an apparent a priori hypothesis and a strong
biological plausibility.We alsominimized population stratiﬁcation
using only Norwegian subjects with Norwegian ancestors in both
case- and control group. Nevertheless, none of our analyses have
shown any statistically signiﬁcant association of the selected SNPs
with TLE, or with the two subgroups TLE-HS or TLE-FS.
Common epilepsies are genetically complex disorders believed
to be inﬂuenced by numerous susceptibility genes, and largely
unknown environmental factors. Examination of selected SNPs
alone does not detail the control of gene expression. In the case of
MMP-9 and this study, the proposed SNP analysis does not touch
upon mechanisms responsible for post-transcriptional regulation,
nor the mechanisms that relate to enzyme activation and
K. Heuser et al. / Seizure 19 (2010) 335–338338inhibition. It is also of note that once activated, MMP-9 can be
inhibited by tissue inhibitors of metalloproteinases (TIMP) and by
TIMP-1 in particular. While studying regulatory factors was
beyond the scope of our study, they might still play a role in
disrupting the mechanisms of MMP-9 secretion, transport and
activation/inhibition. It would be of great interest, therefore, to
assess MMP-9 activity directly in tissue resections from TLE
patients. While several aspects of the role of MMP-9 in both
physiological and pathophysiological states have been unraveled,
there is as yet no evidence from human material that MMP-9 is
involved in the development of epilepsy. Despite a relatively broad
selection of SNPs in the MMP-9 gene of 218 patients, we were
unable to ﬁnd any association with TLE or its two subgroups. The
possibility that TLE is associated with changes in MMP-9
expression or regulation cannot be ruled out and should be
subject to further research.
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